Company Filing History:
Years Active: 2021
Title: Han Na Hong: Innovator in Hepatic Disease Treatment
Introduction
Han Na Hong is a prominent inventor based in Gunpo-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of liver diseases. His innovative work focuses on developing effective therapies for conditions such as hepatitis, hepatic fibrosis, and hepatic cirrhosis.
Latest Patents
Han Na Hong holds 1 patent for a pharmaceutical composition that contains an FGF21 mutant fusion protein. This invention is designed to treat liver diseases, including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein is noted for its ability to inhibit the proliferation of inflammatory cells and fibroblasts, making it a promising candidate for therapeutic applications in liver disease management.
Career Highlights
Han Na Hong is associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on innovative solutions for complex health issues, particularly those affecting liver function.
Collaborations
Han Na Hong collaborates with notable colleagues, including Jun Hwan Kim and Hyun Ho Choi. Their combined expertise contributes to the advancement of research and development in the pharmaceutical sector.
Conclusion
Han Na Hong's contributions to the field of liver disease treatment through his innovative patent highlight the importance of research and development in pharmaceuticals. His work continues to pave the way for new therapeutic options for patients suffering from liver-related conditions.